why choose us

First received: September 29, 2023

Clinical Trial: Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Study Status: Completed

Recruit Status: RECRUITING

Condition: Depression

Study Type: INTERVENTIONAL


Official Title: KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Brief Summary: Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to rapidly improve symptoms in depression.Even a single dose of ketamine has been shown to improve depression and cognition with short-term memory, inhibitory control, cognitive flexibility, and processing speed showing improvements within days of treatment.The mechanism behind ketamine's rapid action is not clear but some groups have speculated it may be related to enhanced neuroplasticity, particularly in the frontal…

Read more